Patient-derived Xenograft Model Market Size, Share & Trends Report

Patient-derived Xenograft Model Market (2025 - 2030) Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts

Market Segmentation

Patient-derived Xenograft Model Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Breast Cancer
- Others
Patient-derived Xenograft Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Mice Model
- Rat Model
Patient-derived Xenograft Model End Use Outlook (Revenue in USD Million, 2018 - 2030)
- Pharmaceutical and Biopharmaceutical Companies
- Academic and Research Institutes
- CRO’s and CDMO’s
Patient-derived Xenograft Model Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Lung Cancer
    - Pancreatic Cancer
    - Prostate Cancer
    - Breast Cancer
    - Others
  - North America Model Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Mice Model
    - Rat Model
  - North America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Academic and Research Institutes
    - CRO’s and CDMO’s
  - U.S.
    - U.S. Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - U.S. Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - U.S. End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Canada
    - Canada Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Canada Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Canada End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Mexico
    - Mexico Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Mexico Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Mexico End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
- Europe
  - Europe Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Lung Cancer
    - Pancreatic Cancer
    - Prostate Cancer
    - Breast Cancer
    - Others
  - Europe Model Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Mice Model
    - Rat Model
  - Europe End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Academic and Research Institutes
    - CRO’s and CDMO’s
  - UK
    - UK Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - UK Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - UK End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Germany
    - Germany Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Germany Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Germany End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - France
    - France Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - France Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - France End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Italy
    - Italy Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Italy Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Italy End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Spain
    - Spain Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Spain Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Spain End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Denmark
    - Denmark Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Denmark Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Denmark End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Norway
    - Norway Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Norway Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Norway End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Sweden
    - Sweden Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Sweden Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Sweden End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
- Asia Pacific
  - Asia Pacific Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Lung Cancer
    - Pancreatic Cancer
    - Prostate Cancer
    - Breast Cancer
    - Others
  - Asia Pacific Model Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Mice Model
    - Rat Model
  - Asia Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Academic and Research Institutes
    - CRO’s and CDMO’s
  - Japan
    - Japan Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Japan Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Japan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - China
    - China Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - China Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - China End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - India
    - India Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - India Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - India End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Australia
    - Australia Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Australia Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Australia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - South Korea
    - South Korea Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - South Korea Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - South Korea End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Thailand
    - Thailand Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Thailand Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Thailand End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
- Latin America
  - Latin America Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Lung Cancer
    - Pancreatic Cancer
    - Prostate Cancer
    - Breast Cancer
    - Others
  - Latin America Model Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Mice Model
    - Rat Model
  - Latin America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Academic and Research Institutes
    - CRO’s and CDMO’s
  - Brazil
    - Brazil Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Brazil Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Brazil End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Argentina
    - Argentina Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Argentina Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Argentina End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
- MEA
  - MEA Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Lung Cancer
    - Pancreatic Cancer
    - Prostate Cancer
    - Breast Cancer
    - Others
  - MEA Model Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Mice Model
    - Rat Model
  - MEA End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Academic and Research Institutes
    - CRO’s and CDMO’s
  - South Africa
    - South Africa Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - South Africa Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - South Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Saudi Arabia
    - Saudi Arabia Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Saudi Arabia Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Saudi Arabia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - UAE
    - UAE Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - UAE Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - UAE End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s
  - Kuwait
    - Kuwait Tumor Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Lung Cancer
      - Pancreatic Cancer
      - Prostate Cancer
      - Breast Cancer
      - Others
    - Kuwait Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Mice Model
      - Rat Model
    - Kuwait End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Academic and Research Institutes
      - CRO’s and CDMO’s

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments